Kyntra Bio (KYNB) Income towards Parent Company (2014 - 2026)

Kyntra Bio has reported Income towards Parent Company for 13 years, with the latest figure at -$66000.0 in Q1 2026.

• Quarterly Income towards Parent Company fell 100.31% year-over-year to -$66000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $220.2 million (up 98.7% YoY) and the FY2025 annual result came in at $241.7 million, up 129.02% from the prior year.
• Income towards Parent Company retreated to -$66000.0 in Q1 2026 per KYNB's latest filing, from $390000.0 in the prior quarter.
• Over five years, Income towards Parent Company peaked at $213.8 million in Q3 2025 and troughed at -$92.9 million in Q4 2023.
• A 5-year average of -$15.9 million and a median of -$66000.0 in 2026 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2025: Income towards Parent Company plunged 286.14% in 2022, then surged 585.02% in 2025.
• Over 5 years, Income towards Parent Company stood at -$66.5 million in 2022, then sank by 39.86% to -$92.9 million in 2023, then soared by 128.67% to $26.6 million in 2024, then plunged by 98.54% to $390000.0 in 2025, then tumbled by 116.92% to -$66000.0 in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$66000.0, $390000.0, and $213.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.